The publication of further analysis in Nature Communications means that hVIVO’s original COVID-19 viral characterisation study continues to enhance understanding of the immune response to SARS-CoV-2 infection and other respiratory viruses. The SARS-CoV-2 characterisation study was conducted by hVIVO, in partnership with Imperial College London, the Vaccine Taskforce and Department of Health and Social Care (DHSC) and the Royal Free London NHS Foundation Trust. The clinical results of the study w ....
